SRPT Earnings Date: Nov 5, 2026 (Estimated) — Sarepta Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is SRPT's next earnings date?
Sarepta Therapeutics, Inc. (SRPT) is expected to report earnings on Thursday, November 5, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.07 on revenue of $352.2M.
How did SRPT do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Sarepta Therapeutics, Inc. posted EPS of $0.64 versus the $0.22 estimate, a beat of 39.1%. Revenue was $401.3M against a $366.4M estimate. The stock's 1-day post-earnings move was +5.3%.
How much does SRPT stock move after earnings?
SRPT beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.9% (up or down) in the day after earnings.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.22 | 0.64 | +39.13% | $401.3M | ✅ Beat | +5.34% | +15.38% | +44.32% |
| 2026-05-06 | Q1 2026 | 0.91 | 3.16 | +247.25% | $730.8M | ✅ Beat | -9.68% | -18.19% | -31.61% |
| 2026-02-25 | Q4 2025 | -0.87 | -3.58 | -311.49% | $442.9M | ❌ Miss | -8.01% | -15.18% | +14.29% |
| 2025-11-03 | Q3 2025 | -0.46 | -0.13 | +71.74% | $399.4M | ✅ Beat | -33.74% | -29.37% | -10.67% |
| 2025-08-06 | Q2 2025 | 1.01 | 2.02 | +100.00% | $611.1M | ✅ Beat | +10.46% | +25.46% | +15.07% |
| 2025-02-26 | Q4 2024 | 1.90 | 1.90 | +0.00% | $658.4M | ➖ Inline | -3.56% | +0.76% | -32.80% |
| 2024-11-06 | Q3 2024 | 0.37 | 0.62 | +67.57% | $467.2M | ✅ Beat | -5.90% | -12.10% | +0.16% |
| 2024-08-07 | Q2 2024 | 0.02 | 0.44 | +2100.00% | $362.9M | ✅ Beat | -2.61% | -4.98% | -7.95% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY21 · $166.9M total
| Segment | Share | Revenue | YoY | Q2 FY21 | Q3 FY21 |
|---|---|---|---|---|---|
| E X O N D Y S Fifty One | 69.3% | $115.6M | — | $112.5M | $115.6M |
| A M O N D Y S Fourty Five | 16.0% | $26.7M | — | $6.9M | $26.7M |
| V Y O N D Y S Fifty Three | 14.8% | $24.7M | — | $22.4M | $24.7M |
By region
Q2 FY26 · $230.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 86.1% | $198.6M | -29.5% | $420.4M | $375.0M | $281.9M | $209.1M |
| Non-US | 13.9% | $32.0M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.